- Home
- CALC vs OGGWZ Comparison
CALC vs OGGWZ Comparison
Compare CALC & OGGWZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CALC | OGGWZ |
|---|---|---|
| Founded | 2011 | N/A |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Precious Metals |
| Sector | Health Care | Basic Materials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 19.1M | 15.3M |
| IPO Year | 2020 | 2008 |
Fundamental Metrics
Financial Performance| Metric | CALC | OGGWZ |
|---|---|---|
| Price | $0.66 | $0.04 |
| Analyst Decision | Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $10.00 | N/A |
| AVG Volume (30 Days) | ★ 283.8K | N/A |
| Earning Date | 05-13-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.46 | N/A |
| 52 Week High | $7.20 | N/A |
Technical Indicators
Market Signals| Indicator | CALC | OGGWZ |
|---|---|---|
| Relative Strength Index (RSI) | 45.59 | N/A |
| Support Level | $0.52 | N/A |
| Resistance Level | $0.77 | N/A |
| Average True Range (ATR) | 0.08 | 0.00 |
| MACD | -0.01 | 0.00 |
| Stochastic Oscillator | 17.08 | 0.00 |
Price Performance
Historical ComparisonAbout CALC CalciMedica Inc.
CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapeutics that treat serious illnesses driven by inflammatory and immunologic processes and direct cellular damage. Its product candidates act upon calcium release-activated calcium (CRAC) channels and would constitute a new class of drugs. Its product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys. The company operates as one operating segment focused on developing and commercializing therapeutics in the U.S.